The Janssen Pharmaceutical announced a strategic decision to discontinue the development of pimodivir, a Phase 3 clinical asset.  What does it mean? More at:

https://www.channelchek.com/news-channel/Cocrystal_Pharma_Inc.__COCP____The_High_Unmet_Need_Persists_in_Influenza